Updated Tuesday, Jan. 13, 2026, to include a statement from the law firm representing Amanda and Chris Medders:
“From day one, our clients acted in good faith, prioritizing patient safety and proper disclosure. They cooperated with investigators, and asked to be informed of any improper practice so they could correct it immediately. As is often the case for small businesses, the cost of litigating to a final verdict would have far exceeded the cost of resolving the case, so the rational business decision was to put the dispute behind us.
“We continue to reject the inflammatory narrative that our clients provided dangerous medications to any patient. Supplier-provided purity tests indicated these products were over 99% pure, and the State did not furnish any purity or contamination test results indicating otherwise. We have seen no evidence that any patients were harmed by any of Aurora’s services. To the contrary, this controversy centered on website phrasing and the content of consent forms-issues our clients were prepared to correct promptly had they been given a pre-suit opportunity to do so.
“This settlement allows everyone to move forward, without any admission of wrongdoing. Aurora and Amanda remain proud of the care they provided to patients and the health goals they helped those patients achieve.“
Carson T. Perreault
Attorney, Huntsville Office
Thompson Burton PLLC
Original story below:
MONTGOMERY, Ala. – Alabama Attorney General Steve Marshall on Monday, Jan. 12, announced the State settled a lawsuit with Aurora IV and Wellness, a Cullman-based IV infusion clinic, and its owners, Amanda and Chris Medders. The lawsuit said the clinic was providing research-grade GLP-1 medications, but advertising them as pharmaceutical-grade.
According to Marshall, the settlement requires the Medderses to pay $17,267.50 in damages to certain consumers who submitted complaints to the attorney general, as well as $7,000 in penalties and fees to the State. The agreement also permanently closes Aurora IV and Wellness and prohibits the Medderses from working in the health care industry in any capacity that involves the direct treatment of patients. Amanda Medders has also surrendered her nursing license to the Board of Nursing.
“Exploiting the need for medical GLP-1 weight-loss medication by using unapproved, research-grade chemicals on unsuspecting patients is an extremely reckless form of consumer deception,” said Marshall. “This type of dangerous disregard for patient safety will not be tolerated in Alabama.”
In November, Marshall announced a temporary restraining order against the business and owners after a lawsuit was filed for violations of Alabama’s Deceptive Trade Practices Act he said constituted serious threats to public health and safety.
“The State’s investigation revealed that the defendants advertised their weight loss drugs – tirzepatide and semaglutide, both GLP-1 medications – as ‘pharmaceutical-grade.’ In reality, the defendants were providing patients with research-grade versions of those drugs that were not approved for human use. The manufacturer of the drugs dispensed by the defendants explicitly stated that the drugs were meant for laboratory research purposes only,” said a media release from Marshall’s office.
Marshall thanked the Alabama Board of Nursing, the Alabama Board of Medical Examiners and the Cullman Police Department for their assistance in the investigation and lawsuit.
